市場調查報告書 - 117225

成體幹細胞和iPS細胞(人工多功能幹細胞)市場:2010年

Adult Stem Cells and iPSCs 2010 Market Report

出版商 SELECTBIO, Ltd. (selectbiosciences.com)
出版日期 2010年03月01日 內容資訊 英文
價格
本報告書已不再販售
成體幹細胞和iPS細胞(人工多功能幹細胞)市場:2010年 Adult Stem Cells and iPSCs 2010 Market Report
出版日期: 2010年03月01日 內容資訊: 英文

本報告已在2013年10月24日停止出版。

簡介

本報告,彙整了成體幹細胞和iPS細胞(人工多功能幹細胞)市場的定量•定性的動向,與全球的智慧財產權、相關法規、治療領域等,由下列摘要形式闡述。

第1章 報告檢視

第2章 成體幹細胞:特性、特徵、市場分析

  • MSC的特性
  • 創造MSC的特徵的標記
  • MSC所調整的免疫調整效果
  • MSC的複合功能
  • MSC調整組織修復的機制
  • 再生醫療上的MSC的作用機制 其他

第3章 心血管疾病

  • 心血管疾病的細胞療法
  • MSC於心血管修復的作用機制
  • 心血管疾病的MSC細胞療法的傳遞途徑
  • 幹細胞療法對於心血管疾病的安全性問題
  • 缺血性症狀的持續以及近年已完成的臨床試驗
  • 再生IHD臨床試驗
  • 肢缺血 其他

第4章 中樞神經疾病

  • 中樞神經疾病的幹細胞療法
  • MSC的神經修復效果
  • 缺血性腦中風的神經幹細胞
  • 慢性兒童型腦硬化症的神經幹細胞

第5章 糖尿病

  • 糖尿病的細胞療法
  • ASC衍生
  • hESC衍生
  • Trans-Differentiation衍生

第6章 iPS細胞

  • iPS細胞領域的里程碑
  • iPS細胞領域的專業用語的定義
  • iPS細胞的優點與缺點
  • 基因重組的小分子
  • 基因重組因素的傳遞法
  • iPS細胞市場分析:創造市場動向特徵的市場調查資料

附錄1:調查方式

附錄2:iPS細胞專利環境

附錄3:EU的iPS細胞相關法規

目錄

Table of Contents

Scope and Description of Chapters in the Report

Chapter I. Executive Overview of the Space

  • 1. Scope of this Market Report
  • 2. Differentiation of ESCs to Clinically-Relevant Populations
  • 3. Timeline of impact of Various Stem Cell Types on the Research and Cellular Therapy Markets
  • 4. Market Sizing and Growth Rate
  • 5. Breakout of Worldwide Stem Cell Industry Revenues in 2010

Chapter II. Adult Stem Cells: Properties, Characteristics, and Market Analysis

  • 1. Properties of MSCs
  • 2. Markers that Characterize MSCs
  • 3. Immunomodulatory Effects Mediated by MSCs
  • 4. Multipotency of MSCs
  • 5. Mechanisms of MSC-mediated Tissue Repair
  • 6. Proposed Mechanism of Action of MSCs in Regenerative Medicine In Vivo
  • 7. Regenerative Medicine Elicited by MSCs
  • 8. 2010 Stem Cell Product Category Market Shares
  • 9. Breakout of Worldwide Clinical Trials Deploying MSCs as Therapeutics: By Disease Area Targeted
  • 10. Breakout of Worldwide Clinical Trials Deploying MSCs as Therapeutics: By Patient Recruitment Status
  • 11. Breakout of Worldwide Clinical Trials Deploying MSCs as Therapeutics: By Clinical Trial Phase
  • 12. Worldwide Clinical Trials Deploying NSCs as Therapeutics
  • 13. Companies Focused in the Regenerative Medicine/Cellular Therapy Space Worldwide: Breakout by Therapeutic Class Addressed
  • 14. Stem Cells Market Segmentation
  • 15. Business Models in the Cellular Therapy Space, Utilizing Adult

Chapter III. Cardiovascular Diseases

  • 1. Cellular Therapy for Cardiovascular Disease
  • 2. Proposed Mechanisms of MSC-Mediated Cardiovascular Repair
  • 3. Potential Delivery Routes of MSC-based Cellular Therapy for Cardiovascular Disease
  • 4. Safety Concerns with Stem Cell Therapy for Cardiovascular Diseases
  • 5. Ongoing and Recently-Completed Clinical Trials for Ischemic Conditions
  • 6. The REGENERATE-IHD Clinical Trial
  • 7. Critical Limb Ischemia
  • 8. IMPACT-DEM Clinical Trial
  • 9. RESTORE-CLI Clinical Trial

Chapter IV. CNS Diseases

  • 1. Stem Cell Treatments for CNS Disorders
  • 2. Neurorestorative Effects of MSCs
  • 3. Neural Stem Cells (NSCs) for Ischemic Stroke
  • 4. NSCs for Pelizaeus - Merzbacher Disease

Chapter V. Diabetes

  • 1. Cellular Therapy of Diabetes
  • 2. ASC - derived
  • 3. hESC - derived
  • 4. Trans - differentiation - derived

Chapter VI. iPSCs

  • 1. Milestones in the iPSCs Space
  • 2. Glossary of Terms in the iPSCs Space
  • 3. Advantages and Challenges of iPSCs Space
  • 4. Small Molecules for Reprogramming
  • 5. Methods of Delivery of Reprogramming Factors
  • 6. iPSCs Market Analysis: Primary Market Survey Data to Characterize Research Market Trends
  • 7. Penetrance of Various hESC Lines in Research Practice Today

Appendix I. Research Methodology

Appendix II. iPSC Patent Landscape

Appendix III. iPSC Requlatory Trends Across the European Union

Back to Top
;